Indian generic manufacturer Marck Biosciences has received a warning letter from the US FDA for failing to pay its annual facility fees for the past two years, which for foreign fixed-dose formulation facilities in 2014 was $235,152 .
Consultoria especializada em GMP/BPF para indústrias voltadas a Ciências da Vida!
Nenhum comentário:
Postar um comentário